205.585 Review of services and treatment for sickle cell disease -- Annual report --

232 words·~1 min read·/ky/205-585

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Short title.

(1)The cabinet shall conduct an annual review of all medications, services, and forms

of treatment for enrollees with a diagnosis of sickle cell disease that are eligible for

coverage under the Kentucky medical assistance program. The purpose of the

annual review shall be to determine if the available covered medications, services,

and treatments are adequate to meet the need of enrollees with a diagnosis of sickle

cell disease and if Department for Medicaid Services should seek to expand

coverage to include additional medications, services, and treatments.

(2)When conducting the annual review required by this section, the cabinet shall solicit

and consider input from the general public with specific emphasis on obtaining

input from individuals or groups with knowledge and experience in the area of

sickle cell disease treatment.

(a)No later than January 15, 2023, and no later than January 15 each year

thereafter, the cabinet shall submit a report to the Legislative Research

Commission for distribution to the appropriate subject matter committees. The

report required by this subsection shall detail the cabinet's findings from the

annual review required by this section and any recommendations based on

those findings.

(b)The cabinet shall make the report required by paragraph

(a)of this subsection

available on its Web site in a manner that is accessible by the general public.

(4)This section may be cited as Emily's Law.